NextCell Pharma publishes its Interim Report 4 2024/2025

October 30, 2025

NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 4 for the period June 1, 2025 – August 31, 2025. The report is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-report. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period in the previous year. . Please note that the Company's financial year is now 1 January - 31 December. This means that for the year 2025, this Q4 report will be followed by a Year-end report at the end of February 2026, covering the period September-December 2025.

Fourth Quarter (2025-06-01 to 2025-08-31)

Operating income amounted to 2,522 (1,696) TSEK, of which Cellaviva contributed 2,600 (1,643) TSEK.
Net sales amounted to 2,600 (1,643) TSEK.
Profit/loss after financial items amounted to -8,481 (-13,249) TSEK.
Earnings per share* were -0.08 (-0.22) SEK.
Cash and cash equivalents amounted to 38,723 (49,970) TSEK.
Equity ratio** amounted to 86 (83) percent.

Twelve Months (2024-09-01 to 2025-08-31)

Operating income amounted to 11,065 (11,278) TSEK, of which Cellaviva contributed 10,937 (10,665) TSEK.
Net sales amounted to 10,937 (10,665) TSEK.
Profit/loss after financial items amounted to -34,992 (-41,960) TSEK.
Earnings per share* were -0.46 (-1.03) SEK.

*Earnings per share: Net result for the period divided by the average number of shares. The average number of shares for the fourth quarter of 2024/2025: 109,746,641 (59,979,085) shares. The average number of shares for the first twelve months of 2024/2025: 76,412,199 (40,814,386) shares. The number of shares in NextCell as of 31 August 2025: 111,392,959 (73,091,327) shares.
**Equity ratio: Shareholders’ equity as a percentage of total assets.

Significant events and news during the fourth quarter

At the beginning of June, the Company announced the outcome of the exercise of TO2 and resolved on directed share issues to guarantors, Through the exercise of the Warrants and the Directed Issue, the Company will receive a total of approximately SEK 36.6 million before deduction of issue costs. Furthermore, the Board of Directors has resolved on a set-off issue of 1,742,100 shares to the guarantors for payment of the guarantee fee.
The Company announced in early June that all patients in the ongoing ProTrans-Young clinical study had been treated. A milestone that marks the completion of dosing in the company's largest clinical study to date. ProTrans-Young is evaluating the safety and efficacy of the company's lead cell therapy candidate, ProTrans, for the treatment of children and adolescents with newly diagnosed type 1 diabetes.Cell and Gene Therapy (ISCT).
In Mid-July the company summoned to an Extraordinary General Meeting in order to change the company's fiscal year to be aligned with the calendar year.

At the end of August, NextCell announced that the Extraordinary General Meeting had resolved to amend the Articles of Association to reschedule the financial year to be 1 January – 31st December.

Significant events and news after the reporting period

At the beginning of September, NextCell announced that the company’s CFO Patrik Fagerholm is leaving his position and that the recruitment process to find a replacement has begun.

This disclosure contains information that NextCell Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 30-10-2025 07:30 CET.

For more information about NextCell Pharma, please contact
Mathias Svahn, CEO
Patrik Fagerholm, CFO
Tel: +46 8 735 5595
E-mail: info@nextcellpharma.com

Websites:
NextCell Pharma AB: www.nextcellpharma.com
Cellaviva Sverige: www.cellaviva.se
Cellaviva Danmark: www.cellaviva.dk
QVance AB: www.qvance.se

LinkedIn: https://www.linkedin.com/company/15255207/
Twitter: https://twitter.com/NextCellPharma

Certified Adviser
The company's shares are listed on the Nasdaq First North Growth Market.
RedEye AB is assigned as Certified Adviser.

About NextCell Pharma AB
NextCell Pharma is a clinical-stage cell therapy company developing ProTrans, a patent-protected platform based on allogeneic mesenchymal stromal cells (MSCs) from umbilical cord tissue. Using a proprietary selection algorithm, ProTrans delivers optimised cell tailored to specific indications. In type 1 diabetes, a single infusion has been shown to preserve insulin production and delay disease progression for at least five years. A Phase III trial is planned to commence upon securing a commercial partner. ProTrans is also being evaluated for other autoimmune and inflammatory conditions. NextCell’s subsidiaries include Cellaviva, Scandinavia’s largest private stem cell bank, and QVance, the Nordic region’s first dedicated provider of quality services for developers of advanced therapies.

Download attachment Read full press release on Cision (external link)

2026-01-21

NextCell provides strategic update on focused market progression, highlighting Hong Kong as gateway to the Chinese market

NextCell Pharma AB (“NextCell” or the “Company”) provides a strategic update on its focused market progression strategy, aimed at accelerating value creation by advancing ProTrans™ in adult patients, where NextCell already has a strong clinical foundation, while simultaneously strengthening the company’s global partnering position. This approach builds on NextCell’s original development strategy and is designed to create multiple independent value drivers for the company.

Read more Read more

2026-01-21

NOTICE OF EXTRAORDINARY GENERAL MEETING IN NEXTCELL PHARMA AB (PUBL)

The shareholders of NextCell Pharma AB (publ), reg. no. 556965-8361, (the "Company") are hereby invited to attend an extraordinary general meeting on Tuesday, 10th of February 2026, at 10:00 CET at Novum-huset, floor 6 (lift E), Hälsovägen 7, Huddinge. Registration for the meeting will commence at 09.30 CET.

Read more Read more

2026-01-21

NextCell decides to propose a directed share issue of SEK 15 million

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, NEW ZEALAND, RUSSIA, SINGAPORE, HONG KONG, JAPAN, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO “IMPORTANT INFORMATION” AT THE END OF THE PRESS RELEASE. The Board of Directors of NextCell Pharma AB (“NextCell” or the “Company”) has resolved to propose to the extraordinary general meeting (the “Extraordinary General Meeting”) to resolve on a directed share issue comprising a total of 15,000,000 shares to a number of strategic investors at a subscription price of SEK 1.00 per share (the “Directed Issue”). Participating investors include both new investors and a number of larger existing shareholders. The Extraordinary General Meeting is planned to be held on Tuesday, 10 February 2026. Notice of the Extraordinary General Meeting will be announced separately.

Read more Read more

2026-01-15

Six-year data demonstrate a durable disease-modifying effect of ProTrans in type 1 diabetes

NextCell Pharma AB (“NextCell” or the “Company”) today announces that six-year follow-up data indicate that a single infusion of ProTrans provides a long-lasting and clinically relevant preservation of endogenous insulin production in patients with newly-diagnosed type 1 diabetes. Patients treated with ProTrans continue to exhibit clinically relevant levels of stimulated C-peptide well beyond expected levels as seen with the natural course of the disease.

Read more Read more

2025-12-09

NextCell in Swedish Life Science Delegation to Hong Kong

NextCell Pharma AB (“NextCell” or “the Company”) is participating in the Swedish life science delegation to Hong Kong on 10–12 December 2025, organised by the Hong Kong Chamber of Commerce in Sweden and the Hong Kong Biotechnology Organisation (HKBIO). The delegation brings together leading Swedish companies to deepen collaborations in research, clinical development, industrial production, and investment in Hong Kong and the Greater Bay Area (GBA).

Read more Read more

2025-12-02

NextCell initiates collaboration with OptiCell – strengthening its cell-handling operations

NextCell Pharma AB (“NextCell” or “the Company”) has entered into a collaboration agreement with OptiCell Solutions AB (“OptiCell”) regarding the handling, freezing, storage, and transport of cell products used for research and development. The collaboration enables NextCell to further leverage its existing infrastructure and expertise in advanced cell handling, also beyond its own clinical projects.

Read more Read more

2025-11-20

NextCell Pharma appoints Eric Gustafsson as new CFO

NextCell Pharma AB (“NextCell” or “the Company”) today announces the appointment of Eric Gustafsson as Chief Financial Officer (CFO). With extensive experience in leading financial transformations and industrial expansion phases within the pharmaceutical industry, Eric brings both strategic and operational expertise that will further strengthen NextCell’s continued growth and development.

Read more Read more

2025-11-19

NextCell Pharma company presentations

NextCell Pharma AB's ("NextCell" or the "Company") CEO Mathias Svahn gave a presentation at the BioStock Life Science Summit 2025 in Lund on November 13[th]. He will also present at Redeye Theme: Autoimmune and Inflammatory Diseases Event later today at 13:05.

Read more Read more